French tech Keen Eye to bring its AI to Iris Pharma in partnership deal

blue eye
Keen Eye will bring its artificial intelligence applications to CRO Iris Pharma as part of a new collaboration. (Pixabay)

French tech company Keen Eye will bring its artificial intelligence applications to Iris Pharma, a CRO focused on ophthalmology, as part of a new collaboration.

Under the agreement, Keen Eye’s AI is expected to make assays much faster and more reliable and efficient. Iris Pharma offers preclinical and clinical services for drug and medical device development.

Financial terms of the deal weren’t disclosed.

WEBINAR

Accelerate Clinical Operations Across Sponsors, CROs and Partners With a Best-of-Breed Partner Like Box

Tuesday, March 24 | 11am ET / 8am PT

Learn how Box is a critical force multiplier in the Best-of-Breed application stack with partners like Nintex, DocuSign and Slack in supporting clinical operations for both regulated and non-regulated content.

“The advanced AI technology of Keen Eye allows us to optimize the performance of the bioimaging analysis during the preclinical ophthalmic drug development, and in the future for clinical development,” Yann Quentric, Iris Pharma’s president, said in a statement.

“We are expecting to contribute to the most challenging image-based assays to better fight eye diseases,” Keen Eye’s founder and chief executive, Sylvain Berlemont, added.

Iris, which is also headquartered in France, is a full-service research organization with a long history of helping to get ocular drugs and devices onto the market.

Suggested Articles

The ruling reflects the judge’s belief that the FDA’s interpretation of the law on clinical trial reporting “is unlawful and must be set aside.”

Clinical trial data specialist IQVIA has boosted its clinical research network in the U.S. and India.

Clinerion has penned a deal to tap Wefight’s so-called Vik app to help seek out patients and play matchmaker for them to join clinical trials.